NGNE 54.60 Neurogene Inc.
| Range: | 12.49-53.0 | Vol Avg: | 114043 | Last Div: | 0 | Changes: | 1.28 |
| Beta: | 0 | Cap: | 0.64B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Fri Mar 07 2014 | Empoloyees: | 91 | ||
| CUSIP: | 64135M105 | CIK: | 0001404644 | ISIN: | US64135M1053 | Country: | US |
| CEO: | Dr. Rachel L. McMinn Ph.D. | Website: | https://www.neurogene.com | ||||
Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.
Stock Details
NGNE 49
Neurogene price target lowered to $49 from $51 at H.C. Wainwright
Mitchell Kapoor·Mon Aug 12 2024
H.C. Wainwright
NGNE 65
BMO Capital Starts Neurogene (NGNE) at Outperform
Keith Tapper·Wed Jun 26 2024
BMO Capital
NGNE 54
Baird Starts Neurogene (NGNE) at Outperform
Joel Beatty·Mon Jun 10 2024
Robert W. Baird
NGNE 51
Neurogene (NGNE) PT Lowered to $51 at H.C. Wainwright
Mitchel Kapoor·Mon May 13 2024
H.C. Wainwright
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow